Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

ARQT Stock Performance - Arcutis' stock has surged over 272% in the past year, significantly outperforming the industry's 14 1% decline [1] - The stock's rise is primarily driven by positive regulatory updates regarding the expansion of Zoryve's label [6] ARQT's Zoryve Product - Zoryve is currently approved in different formulations (foam and cream) for various indications [6] - A 0 3% formulation of Zoryve cream is approved for plaque psoriasis in patients six years and older and for seborrheic dermatitis in patients nine years and above [9] - A 0 15% formulation of Zoryve cream was approved in July for mild to moderate atopic dermatitis (AD) in patients six years and older [9] - A 0 15% formulation of Zoryve foam is approved for seborrheic dermatitis in individuals aged nine years and older [9] ARQT's Regulatory Updates - Arcutis submitted an sNDA to the FDA for Zoryve cream 0 05% to treat mild to moderate AD in children two to five years old [7] - An sNDA for Zoryve foam 0 3% to treat scalp and body psoriasis is under FDA review, with a final decision expected in May 2025 [7] - Potential approvals for these indications are expected to boost revenues in 2025 [7] ARQT's Financial Performance - Zoryve has driven strong revenue growth, with product revenues reaching $97 million in the first nine months of 2024, up more than 500$1 59 to $1 29 and its 2025 loss per share estimates narrow from$1 54 to 79 cents in the past 60 days [8] - SPRO's shares have lost 26 5% in the past year, and its earnings have beaten estimates in two of the trailing four quarters, with an average surprise of 94 42% [8] - CytomX Therapeutics (CTMX) has seen its 2024 loss per share estimates narrow from 29 cents to 5 cents and its 2025 loss per share estimates narrow from 56 cents to 35 cents in the past 60 days [3] - CTMX's shares have lost 34 9% in the past year, and its earnings have beaten estimates in two of the trailing four quarters, with an average surprise of 115 70% [3] Zacks Rankings - Arcutis currently carries a Zacks Rank 3 (Hold) [2] - Castle Biosciences (CSTL) and Spero Therapeutics (SPRO) sport a Zacks Rank 1 (Strong Buy), while CytomX Therapeutics (CTMX) carries a Zacks Rank 2 (Buy) [12]